Sun Pharmaceutical Industries reported a 26.24% year-on-year (YoY) rise in consolidated net profit to ₹2,714.03 crore for the March quarter of FY26.
The company had posted a profit of ₹2,149.88 crore in the same quarter last year.
However, on a quarter-on-quarter (QoQ) basis, profit declined 19.44% from ₹3,368.81 crore reported in Q3FY26.
Revenue from operations increased 12.8% YoY to ₹14,611.79 crore during the quarter under review.
In comparison, revenue stood at ₹12,958.84 crore in Q4FY25. On a sequential basis, revenue declined 5.9% from ₹15,520.54 crore reported in the December quarter.
The company’s sales grew 13.6% YoY to ₹14,559.8 crore during the quarter.
EBITDA for Q4FY26 rose 6.4% YoY to ₹3,955 crore.
However, EBITDA margin slipped to 27.1% from 28.7% in the same quarter last year.
For the full financial year FY26, Sun Pharmaceutical Industries reported a 5% increase in net profit to ₹11,479.4 crore.
Annual sales rose 11.9% YoY to ₹58,220.1 crore.
The company’s EBITDA increased 16.1% YoY to ₹17,731.4 crore, while EBITDA margin improved to 30.3% from 29% in FY25.
The board of Sun Pharmaceutical Industries recommended a final dividend of ₹5 per share of face value ₹1 each for FY26.
This is in addition to the interim dividend of ₹11 per share already paid during the year, taking the total FY26 dividend payout to ₹16 per share, unchanged from FY25.
Sun Pharma said its India formulations business grew 14.8%, supported by strong performance in cardiovascular, central nervous system, gastro, and orthopaedic segments.
US formulations revenue declined slightly to $459 million during the quarter.
India formulations contributed 33% of total consolidated sales in FY26, while the US business accounted for 29%.
The company’s emerging markets business grew 13.6% to $1.27 billion during FY26.
Read More: Welspun Corp Share Price in Focus; Bags ₹700 Crore LSAW Pipe Order from US Facility!
Sun Pharmaceutical Industries share price (NSE: SUNPHARMA) closed at ₹1,840 on Thursday, down 2.71% or ₹51.30 for the day. The stock opened at ₹1,903 and touched an intraday high of ₹1,903 and a low of ₹1,833.10. The company’s market capitalisation stood at ₹4.43 lakh crore, while its price-to-earnings (P/E) ratio was 40.48. The stock has a 52-week high of ₹1,916.60 and a 52-week low of ₹1,548. The company offers a dividend yield of 0.90%, with a quarterly dividend amount of ₹4.14 per share.
Sun Pharmaceutical Industries delivered strong Q4 profit growth supported by higher sales and steady demand in domestic markets. The company also maintained its dividend payout while reporting healthy annual revenue and EBITDA growth in FY26.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 22, 2026, 4:36 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
